Unknown

Dataset Information

0

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.


ABSTRACT: Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults.Thirty volunteers (aged 50-85) received a single intramuscular injection of MVA-NP+M1 at a dose of 1·5×10(8) plaque forming units (pfu). Safety and immunogenicity were assessed over a period of one year. The frequency of T cells specific for nucleoprotein (NP) and matrix protein 1 (M1) was determined by interferon-gamma (IFN-?) ELISpot, and their phenotypic and functional properties were characterized by polychromatic flow cytometry. In a subset of M1-specific CD8(+) T cells, T cell receptor (TCR) gene expression was evaluated using an unbiased molecular approach.Vaccination with MVA-NP+M1 was well tolerated. ELISpot responses were boosted significantly above baseline following vaccination. Increases were detected in both CD4(+) and CD8(+) T cell subsets. Clonality studies indicated that MVA-NP+M1 expanded pre-existing memory CD8(+) T cells, which displayed a predominant CD27(+)CD45RO(+)CD57(-)CCR7(-) phenotype both before and after vaccination.MVA-NP+M1 is safe and immunogenic in older adults. Unlike seasonal influenza vaccination, the immune responses generated by MVA-NP+M1 are similar between younger and older individuals. A T cell-inducing vaccine such as MVA-NP+M1 may therefore provide a way to circumvent the immunosenescence that impairs routine influenza vaccination.ClinicalTrials.gov NCT00942071.

SUBMITTER: Antrobus RD 

PROVIDER: S-EPMC3485192 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

Antrobus Richard D RD   Lillie Patrick J PJ   Berthoud Tamara K TK   Spencer Alexandra J AJ   McLaren James E JE   Ladell Kristin K   Lambe Teresa T   Milicic Anita A   Price David A DA   Hill Adrian V S AV   Gilbert Sarah C SC  

PloS one 20121031 10


<h4>Background</h4>Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults.<h4>Methods</h4>Thirty volunteers (aged 50-85) received a single intramuscular injection of MVA-NP+M1 at a dose of 1·5×10(8) plaque forming units (pfu). Safety and immunogenicity were assessed over a period of one year  ...[more]

Similar Datasets

| S-EPMC3060888 | biostudies-literature
| S-EPMC6466103 | biostudies-literature
| S-EPMC3256327 | biostudies-literature
| S-EPMC5989887 | biostudies-literature
| S-EPMC3369564 | biostudies-literature
| S-EPMC3978791 | biostudies-literature
| S-EPMC9942430 | biostudies-literature
| S-EPMC9270321 | biostudies-literature
| S-EPMC9570979 | biostudies-literature
| S-EPMC4453684 | biostudies-other